Abstract
In the CoreValve US Pivotal High-Risk Trial, patients with severe aortic stenosis (AS) had similar clinical outcomes with TAVR or SAVR over 5 years of follow-up, with mortality rates of ~55% in both groups. The long-term health status of surviving patients has not been described. Among high risk
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
